Franck Dubin
About
Franck Dubin is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Franck Dubin has authored 18 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 12 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Franck Dubin's work include Multiple Myeloma Research and Treatments (15 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Peptidase Inhibition and Analysis (7 papers). Franck Dubin is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Peptidase Inhibition and Analysis (7 papers). Franck Dubin collaborates with scholars based in France, United States and Türkiye. Franck Dubin's co-authors include Paul G. Richardson, Frank Campana, Kenneth C. Anderson, Dorothée Sémiond, William Bensinger, Saad Z. Usmani, Joseph Mıkhael, Noopur Raje, Chatchada Karanes and Qianying Liu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.
In The Last Decade
Franck Dubin
16 papers receiving 236 citations
Peers
Franck Dubin
Jeroen Lammerts van Bueren Netherlands
Kristi Elkins United Kingdom
Sunita Philip United States
Sunil Gandhi United States
Joseph Kauer Germany
Stefan Koehrer United States
Marcus Lefebure United States
J. Infante United States
Christine Greil Germany
Rayan Kaedbey Canada
Citations per year, relative to Franck Dubin Franck Dubin (= 1×)
peers
Jeroen Lammerts van Bueren
Countries citing papers authored by Franck Dubin
Since
Specialization
Citations
This map shows the geographic impact of Franck Dubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck Dubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck Dubin more than expected).
Fields of papers citing papers by Franck Dubin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Franck Dubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck Dubin. The network helps show where Franck Dubin may publish in the future.
Co-authorship network of co-authors of Franck Dubin
This figure shows the co-authorship network connecting the top 25 collaborators of Franck Dubin. A scholar is included among the top collaborators of Franck Dubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck Dubin. Franck Dubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Richardson, Paul G., Aurore Perrot, Jesús F. San Miguel, et al.. (2024). Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 109(7). 2239–2249.
2.
Moreau, Philippe, Aurore Perrot, Meletios Α. Dimopoulos, et al.. (2023). P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS. HemaSphere. 7(S3). e27700c7–e27700c7.
3.
Richardson, Paul G., Aurore Perrot, Jesús F. San Miguel, et al.. (2022). Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies. Blood. 140(Supplement 1). 608–610.
4.
Richardson, Paul G., Aurore Perrot, Jesús F. San Miguel, et al.. (2022). OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis. Clinical Lymphoma Myeloma & Leukemia. 22. S32–S32.
5.
Usmani, Saad Z., Chatchada Karanes, William Bensinger, et al.. (2021). Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 35(12). 3526–3533.
6.
Richardson, Paul G., Aurore Perrot, Jesús F. San Miguel, et al.. (2021). Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 39(15_suppl). 8017–8017.
7.
Richardson, Paul G., Aurore Perrot, Jesús F. San Miguel, et al.. (2021). MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 21. S423–S424.
8.
Usmani, Saad Z., Chatchada Karanes, William Bensinger, et al.. (2020). MM-096: Isatuximab Short-Duration Fixed-Volume Infusion Combination Therapy for Relapsed/Refractory Multiple Myeloma: Final Results of a Phase 1b Feasibility/Safety Study. Clinical Lymphoma Myeloma & Leukemia. 20. S291–S291.
9.
Usmani, Saad Z., Chatchada Karanes, William Bensinger, et al.. (2019). Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study. Clinical Lymphoma Myeloma & Leukemia. 19(10). e283–e283.
10.
Attal, Michel, Paul G. Richardson, S. Vincent Rajkumar, et al.. (2019). S824 A PHASE 3 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW‐DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW‐DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). HemaSphere. 3(S1). 365–365.
11.
Mıkhael, Joseph, Paul G. Richardson, Saad Z. Usmani, et al.. (2019). A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 134(2). 123–133.
12.
Richardson, Paul G., Michel Attal, S. Vincent Rajkumar, et al.. (2019). A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 37(15_suppl). 8004–8004.
13.
Mıkhael, Joseph, Paul G. Richardson, Saad Z. Usmani, et al.. (2018). Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 36(15_suppl). 8038–8038.
14.
Richardson, Paul, Joseph Mıkhael, Saad Z. Usmani, et al.. (2017). Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 17(1). e16–e17.
15.
Richardson, Paul G., Joseph Mıkhael, Saad Z. Usmani, et al.. (2016). Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood. 128(22). 2123–2123.
16.
Villanueva, Cristian, Ahmad Awada, Mario Campone, et al.. (2011). A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study. European Journal of Cancer. 47(7). 1037–1045.
17.
Besse‐Hammer, Tatiana, Cristian Villanueva, Mario Campone, et al.. (2009). A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results. Journal of Clinical Oncology. 27(15_suppl). 1053–1053.
18.
Villanueva, Cristian, Ahmad Awada, Mario Campone, et al.. (2009). 5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy. European Journal of Cancer Supplements. 7(2). 268–268.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jeroen Lammerts van Bueren Breakdown of academic impact, for papers by Kristi Elkins Breakdown of academic impact, for papers by Sunita Philip Breakdown of academic impact, for papers by Sunil Gandhi Breakdown of academic impact, for papers by Joseph Kauer Breakdown of academic impact, for papers by Stefan Koehrer Breakdown of academic impact, for papers by Marcus Lefebure Breakdown of academic impact, for papers by J. Infante Breakdown of academic impact, for papers by Christine Greil Breakdown of academic impact, for papers by Rayan Kaedbey